Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
Portfolio Pulse from Lisa Levin
The article lists the top 5 oversold health care stocks, which are Sharecare, Inc. (SHCR), Brainstorm Cell Therapeutics Inc. (BCLI), Cosmos Health Inc. (COSM), Beyond Air, Inc. (XAIR), and Protagonist Therapeutics, Inc. (PTGX). These stocks are considered oversold as their Relative Strength Index (RSI) is near or below 30. The companies have recently reported various financial results and offerings.
July 27, 2023 | 11:46 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Brainstorm Cell Therapeutics announced a $7.5 million registered direct offering and its stock fell 3.6% to close at $1.63 on Wednesday.
The company's direct offering could dilute existing shares, which may have contributed to the stock price fall.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Cosmos Health priced a $5.25 million registered direct offering and private placement at $2.48. Its stock fell 4.1% to close at $1.63 on Wednesday.
The company's direct offering and private placement could dilute existing shares, which may have contributed to the stock price fall.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Protagonist Therapeutics reported acceptance of a late-breaking abstract for presentation at the 2023 EHA Congress. Its stock fell 1.2% to close at $19.13 on Wednesday.
The company's announcement about the abstract acceptance is a positive development, but the stock price fell, indicating a negative market reaction.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Sharecare posted a narrower-than-expected Q1 loss and its stock fell 3.7% to close at $1.30 on Wednesday.
The company's narrower-than-expected loss indicates a better financial performance, but the stock price fell, indicating a negative market reaction.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Beyond Air reported worse-than-expected Q4 EPS results and its stock fell 1.2% to close at $3.45 on Wednesday.
The company's worse-than-expected EPS results indicate a poor financial performance, which may have contributed to the stock price fall.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100